WuXi Receives 2015 Asian CRO Company of the Year Award from Frost & Sullivan

We are thrilled to share with you that we have been awarded the 2015 Frost & Sullivan Asian CRO Company of the Year Award.  The award is part of the Frost...

WuXi and Lilly Collaborate to Develop Novel Therapeutics in China

We are pleased to share with you that we have entered into a strategic collaboration with Eli Lilly and Company to develop, manufacture and commercialize a novel small molecule in China...

Gilead Sciences and WuXi Partner for a Dedicated Analytical and Stability Testing Facility

We are pleased to announce that we have entered into a strategic partnership with Gilead Sciences to conduct analytical and stability studies of small-molecule new chemical entities to support global marketing...

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

WUXI NEWS

WuXi NextCODE Completes $240 Million Series B Financing

We are pleased to announce that WuXi NextCODE has successfully completed a $240 million Series B financing. The company extended and completed the Series...